RENO, Nev., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an
RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a
Company advances manufacturing scale-up, regulatory testing and preclinical work supporting its planned FDA 510(k) submission in the first quarter of 2027.Multiple scaled-up batches of CXU™ material met predefined
NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size
RENO, Nev., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a preclinical-stage biotechnology company advancing an investigational
Issued on behalf of Conexeu Sciences Inc. NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - For as long as aesthetic medicine has existed, its central promise has been to replace what time
NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - The most valuable companies of the past two decades share a trait that is easy to miss: they didn’t win by competing inside an existing
Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu’s CXU™ Platform Highlights
RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - The weight-loss drug boom has been one of the defining healthcare stories of the decade, and its success has created a second-order
RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy
RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a preclinical-stage biotechnology company advancing an investigational tissue-restoration
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator
Issued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) is aiming its investigational CXU™ platform at the largest unclaimed frontier in injectable aesthetics: restoring real body volume at a scale
Issued on behalf of Conexeu Sciences Inc. As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (NASDAQ:CNXU)
Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed. History demonstrates the value of
